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More than 15% of cancer deaths worldwide are associated with underlying infections or inflammatory con-
ditions, therefore understanding how inflammation contributes to cancer etiology is important for both 
cancer prevention and treatment. Inflamed tissues are known to harbor elevated etheno-base (ε-base) DNA 
lesions induced by the lipid peroxidation that is stimulated by reactive oxygen and nitrogen species (RONS) 
released from activated neutrophils and macrophages. Inflammation contributes to carcinogenesis in part via 
RONS-induced cytotoxic and mutagenic DNA lesions, including ε-base lesions. The mouse alkyl adenine DNA 
glycosylase (AAG, also known as MPG) recognizes such base lesions, thus protecting against inflammation-
associated colon cancer. Two other DNA repair enzymes are known to repair ε-base lesions, namely ALKBH2 
and ALKBH3; thus, we sought to determine whether these DNA dioxygenase enzymes could protect against 
chronic inflammation-mediated colon carcinogenesis. Using established chemically induced colitis and colon 
cancer models in mice, we show here that ALKBH2 and ALKBH3 provide cancer protection similar to that of 
the DNA glycosylase AAG. Moreover, Alkbh2 and Alkbh3 each display apparent epistasis with Aag. Surprisingly, 
deficiency in all 3 DNA repair enzymes confers a massively synergistic phenotype, such that animals lacking 
all 3 DNA repair enzymes cannot survive even a single bout of chemically induced colitis.
Introduction
Chronic inflammation is associated with an increased risk of can-
cer, and more than 15% of cancer deaths worldwide are associated 
with an underlying infection or inflammatory condition (1, 2). For 
example, patients with inflammatory bowel disease (IBD), encom-
passing both ulcerative colitis (UC) and Crohn’s disease, have an 
increased susceptibility to colorectal cancer; indeed, patients with 
extensive UC are at least 3- to 5-fold more likely to develop colorec-
tal cancer than the general population (3). Further, the risk of colon 
cancer in patients with UC increases with the severity and duration 
of the inflammatory disease (4, 5). The association between cancer 
and intestinal inflammation is further strengthened by the fact 
that controlling or inhibiting inflammation in patients with IBD 
with long-term use of antiinflammatory drugs, such as nonsteroi-
dal antiinflammatory drugs and selective cyclooxygenase-2 inhibi-
tors, reduces cancer risk by 40%–50% (6, 7).
Increased levels of DNA base lesions have been documented in 
patients with chronic inflammatory conditions, including IBD 
(8–10). During an episodic inflammatory flare-up in patients 
with IBD, uncontrolled inflammation can cause tissue damage by 
the secretion of proinflammatory cytokines, chemokines, growth 
factors, and matrix-degrading enzymes. Importantly, such flare-
ups also generate large quantities of reactive oxygen and nitrogen 
species (RONS) (11). RONS can directly induce DNA damage via 
oxidation and deamination of DNA bases, but, in addition, base 
damage occurs indirectly via lipid peroxidation; RONS react with 
polyunsaturated fatty acids to generate DNA-reactive aldehydes, 
including malondialdehyde and 4-hydroxy-2-nonenal (12). The 
terminal reaction of these aldehydes with DNA generates muta-
genic and toxic etheno-base (ε-base) lesions and other exocyclic 
DNA adducts (13, 14). Moreover, RONS also induce the forma-
tion of nitrosamines that may methylate DNA (15, 16). Therefore, 
chronic inflammation, through multiple mechanisms, results in 
increased levels of 1,N6-ethenoadenine (εA), 1,N2-ethenoguanine 
(1,N2-εG), 3,N4-ethenocytosine (εC), 7,8-dihydro-8-oxoguanine 
(8oxoG), and possibly methylated base lesions in the DNA of 
affected tissues (8, 17, 18). In fact, patients with IBD exhibit 2- to 
20-fold increases in εC adducts in colonic tissue compared with 
that in healthy controls (19). Evidence of systemic DNA damage 
is also suggested from the observation of increased DNA damage 
in peripheral leukocytes as well as the presence of DNA adducts in 
the urine during chronic inflammation (18, 20).
In a previous mouse study, we found that the mouse alkylad-
enine DNA glycosylase (AAG, also known as MPG and ANPG), 
which recognizes both ε-base and methylated base lesions, reduces 
colon damage and decreases tumor burden in response to chron-
ic colonic inflammation (10). AAG initiates base excision repair 
and excises a wide range of structurally diverse damaged bases, 
including 3-methyladenine, 7-methylguanine, εA, 1,N2-εG, hypo-
xanthine, and 8oxoG, among others; in addition, AAG binds εC 
lesions with high affinity but cannot excise them from DNA (Fig-
ure 1 and refs. 21–30). In fact, we observed a greater accumula-
tion of ε-adducted and oxidized DNA base lesions in the colonic 
epithelium of Aag–/– mice after an inflammation challenge when 
Authorship note: Jennifer A. Calvo and Lisiane B. Meira are co–first authors.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2012;122(7):2680–2689. doi:10.1172/JCI63338.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 7   July 2012 2681
compared with those in WT mice (10). Moreover Aag–/– mice suf-
fered increased colon tissue damage and elevated tumorigenesis 
compared with WT mice, indicating that the repair of inflamma-
tion-induced DNA lesions is important for colon cancer preven-
tion. As mentioned, AAG tightly binds but is incapable of excising 
εC lesions (29, 31). Interestingly, we observed that following an 
intestinal inflammatory challenge, Aag–/– colons accumulate higher 
levels of εC, compared with that in WT colons, suggesting that 
AAG-εC binding somehow facilitates εC repair (10). It is possible 
that, although AAG does not directly excise εC, it may assist in its 
repair by recruiting other proteins to repair this RONS-induced 
εC DNA base lesion.
The E. coli AlkB DNA repair enzyme can repair ε-base lesions, 
such as εA and εC (32), in addition to simple alkylated adducts, 
such as 1-methyladenine and 3-methylcytosine (Figure 1 and refs. 
33–36); repair is via a direct reversal oxidative demethylation reac-
tion that is dependent on oxygen, iron, and α-ketoglutarate (33, 
34). The preferred substrates for the human AlkB homologs (the 
ALKBH proteins) are still being elucidated, but it has been dem-
onstrated that ALKBH2 repairs εA both in vivo and in vitro and 
that ALKBH3 repairs εA at least in vitro (Figure 1 and refs. 37, 
38). Recently, ALKBH3-mediated DNA repair in vivo was shown 
to be coupled to DNA unwinding by the ASCC3 helicase (39). 
In addition, we recently showed that ALKBH2 efficiently repairs 
εC adducts in vitro (40). Since the mouse ALKBH2 and ALKBH3 
enzymes are also likely to repair ε-base lesions, we sought to 
determine whether ALKBH2 and ALKBH3, like AAG, can protect 
against chronic inflammation-mediated colon carcinogenesis. It 
is important to note that in the absence of AAG, ε-base lesions 
continue to be removed from the genome, albeit very slowly (41, 
42); we therefore hypothesized that ALKBH2 and ALKBH3 may be 
responsible for such redundant repair. To assess this, we induced 
chronic inflammatory colitis in Aag, Alkbh2, and Alkbh3 single-, 
double-, and triple-knockout mice, monitoring various aspects 
of colitis and colorectal cancer. Our results demonstrate that 
ALKBH2 and ALKBH3 modestly protect against inflammation-
mediated colon carcinogenesis and that their effects are at least 
additive in the Alkbh2/Alkbh3 double-knockout mice. We also 
show that Aag appears to have an epistatic relationship with Alkbh2 
and Alkbh3, because the addition of Alkbh2 or Alkbh3 mutations 
into the Aag–/– background did not exacerbate the phenotype. 
Most notably, we have uncovered a remarkable synergism among 
AAG, ALKBH2, and ALKBH3 in protecting against acute intes-
tinal damage, as indicated by the inability of the Aag–/–Alkbh2–/– 
Alkbh3–/– triple mutant mice to recover from even a single bout of 
colitis induced by dextran sodium sulfate (DSS).
Results
ALKBH2 and ALKBH3 protect against azoxymethane/DSS-medi-
ated colon carcinogenesis. To determine whether the ALKBH2 or 
ALKBH3 enzymes play a protective role in chronic inflammation-
associated carcinogenesis, we challenged Alkbh2–/–, Alkbh3–/–, and 
Alkbh2–/–Alkbh3–/– mice with the azoxymethane/DSS (AOM/DSS) 
treatment regimen. This 2-step carcinogenesis protocol has been 
extensively used to study inflammation-associated colon carcino-
genesis (10, 43, 44); AOM acts as an initiator, and DSS, by per-
turbing the intestinal mucosal layer, enables enteric bacteria to 
elicit colonic inflammation. It is important to note that using our 
experimental conditions, neither AOM nor DSS alone significantly 
induce carcinogenesis in WT animals (10). Alkbh2–/–, Alkbh3–/–, and 
Alkbh2–/–Alkbh3–/– mice all exhibited greater sensitivity to AOM/
DSS than WT mice, as indicated by decreased survival (P < 0.05) 
(Figure 2A). In fact, only 40% to 60% of Alkbh2–/–, Alkbh3–/–, and 
Alkbh2–/–Alkbh3–/– mice survived the entire treatment regimen com-
pared with 80% of WT mice. Pathological data obtained from the 
mice euthanized during the experiment were combined with data 
obtained from mice that survived the entire experiment, because 
there were few statistically significant differences between the 2 
groups in each of the following colon disease criteria: histopatho-
logical scores, spleen weight, colon length, and tumor multiplic-
ity (Supplemental Table 1; supplemental material available online 
with this article; doi:10.1172/JCI63338DS1).
All Alkbh-deficient mice (Alkbh2–/–, Alkbh3–/–, and Alkbh2–/–Alkbh3–/– 
mice) exhibited significant increases in spleen weight when com-
pared with that of WT mice following AOM/DSS treatment 
(Figure 2B). Increased spleen weight is a common end point for 
colitis studies and reflects extramedullary hematopoiesis in the 
spleen plus lymphoid hyperplasia, a mechanism for coping with 
recurrent blood loss in the stools, as well as possible immune 
activation in the spleen. We also observed an additive increase in 
spleen weight in the Alkbh2–/–Alkbh3–/– mice, which exhibited sig-
nificantly larger spleen weights compared with those of Alkbh3–/– 
mice (P = 0.0126) and trended toward an increase compared with 
Alkbh2–/– mice (P = 0.167) (Figure 2B).
Our previous studies illustrated that both the AOM and DSS 
challenges are required to induce significant colon tumorigen-
esis (10). Accordingly, AOM/DSS treatment resulted in colon 
tumors in the majority of mice for each genotype; 83% of WT, 
93% of Alkbh3–/–, and 100% of Alkbh2–/– and Alkbh2–/–Alkbh3–/– 
mice developed tumors in the distal colon (Figure 2C). Mice 
lacking ALKBH2 are more susceptible than WT mice to colon 
tumorigenesis, as illustrated by increased tumor multiplicity 
Figure 1
Published nucleic acid substrates for the AAG, ALKBH2, and ALKBH3 
enzymes. Substrates for the AAG, ALKBH2, and ALKBH3 enzymes 
have been illustrated either in vitro or in vivo, including 3-methylad-
enine (3MeA), 7-methylguanine (7MeG), hypoxanthine (Hx), 8oxoG, 
1,N6-ethanoadenine (EA), 1,N2-εG, 1-methylguanine (1MeG), εC, εA, 
3-methylthymine (3MeT), 1-methyladenine (1MeA), and 3-methylcyto-
sine (3MeC). The asterisk indicates that AAG binds but is unable to 
excise εC base lesions. Lesions listed in yellow are known substrates of 
bacterial AlkB; ALKBH2 or ALKBH3 have yet to be tested for the ability 
to excise these lesions. ds, double strand; ss, single strand.
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(P = 0.041) (Figure 2C). In contrast, Alkbh3–/– mice did not devel-
op significantly more tumors than WT mice (P = 0.269). Despite 
this, an ALKBH3 deficiency did contribute to disease progres-
sion in the absence of ALKBH2, since we observed a synergistic 
increase in tumor induction in Alkbh2–/–Alkbh3–/– mice, when 
compared with that in either Alkbh2–/– (P = 0.005) or Alkbh3–/– 
mice (P < 0.001). Taken together, these results show that both 
the ALKBH2 and ALKBH3 DNA repair proteins protect against 
inflammation-associated colon carcinogenesis.
Histopathological analysis of colon tissue revealed an additive 
increase in hyperplasia in Alkbh2–/–Alkbh3–/– mice compared with 
that in the single mutants and an increase in the criteria of dys-
plasia/neoplasia and area affected compared with that in WT and 
Alkbh3–/– mice following the AOM/DSS treatment (Supplemen-
tal Figure 1A). Alkbh2–/– mice also exhibited increased scores for 
dysplasia/neoplasia and area affected compared with those of WT 
mice. Although Alkbh3–/– mice exhibited an increase in the inflam-
mation score, compared with that of all other genotypes, as well 
as increased spleen weight and decreased colon length, this single 
mutant did not exhibit significant increases in tumor multiplicity 
or other histopathological criteria compared with WT mice.
AAG and ALKBH enzymes exhibit overlap in their protection against 
AOM/DSS-mediated colon carcinogenesis. Given the overlap in sub-
strate specificity between the ALKBH enzymes and AAG (Figure 1), 
Figure 2
ALKBH proteins are protective against AOM/
DSS-mediated carcinogenesis. (A) Kaplan-
Meier survival curves show that during AOM/
DSS treatment, compared with that for WT 
mice, there is a significant decrease in survival 
for Alkbh2–/– (P < 0.0001), Alkbh3–/– (P < 0.05), 
and Alkbh2–/–Alkbh3–/– (P < 0.0001). (B) Spleen 
weight as a percentage of body weight is plot-
ted for WT (n = 36), Alkbh2–/– (n = 13), Alkbh3–/– 
(n = 26), and Alkbh2–/–Alkbh3–/– mice (n = 17). 
Data represent mean ± SEM. (C) Tumor multi-
plicity is presented as the number of tumors 
per mouse in WT (n = 31), Alkbh2–/– (n = 13), 
Alkbh3–/– (n = 25), and Alkbh2–/–Alkbh3–/– mice 
(n = 16). Data is presented as mean ± SEM.
Figure 3
Aag–/–, Aag–/–Alkbh2–/–, and Aag–/–Alkbh3–/– 
mice all exhibit increased susceptibility to 
AOM/DSS treatment. (A) Kaplan-Meier surviv-
al curves show decreased survival for Aag–/–, 
Aag–/–Alkbh2–/–, and Aag–/–Alkbh3–/– mice com-
pared with that for WT mice during the AOM/
DSS treatment. (B) The change in colon length 
as compared with that in untreated controls is 
plotted for WT (n = 18), Aag–/– (n = 9), Aag–/– 
Alkbh2–/– (n = 20), and Aag–/–Alkbh3–/– mice 
(n = 9). Data represent mean ± SEM. (C) 
Tumor multiplicity is presented as the number 
of tumors per mouse in WT (n = 18), Aag–/– 
(n = 9), Aag–/–Alkbh2–/– (n = 19), and Aag–/–
Alkbh3–/– mice (n = 9). Data is presented as 
mean ± SEM.
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we investigated whether the absence of Alkbh2 or Alkbh3 in an 
Aag-deficient background might result in further susceptibil-
ity to AOM/DSS treatment compared with Aag–/– mice (10). We 
treated WT, Aag–/–, Aag–/–Alkbh2–/–, and Aag–/–Alkbh3–/– mice with 
AOM/DSS. Compared with WT mice, all 3 repair-deficient strains 
exhibited greater sensitivity to the AOM/DSS treatment, as 
shown by decreased survival that is similar for all 3 mutant strains 
(P < 0.0001) (Figure 3A). Again, since the histopathological and 
other disease end points did not differ significantly with length 
of survival, we combined data from mice euthanized mid-treat-
ment with data from mice euthanized after the end of treatment 
(Supplemental Table 2). The spleen weights were similar for all 
of the genotypes (data not shown). However, as demonstrated 
in Figure 3B, all 3 genotypes (Aag–/–, Aag–/–Alkbh2–/–, and Aag–/– 
Alkbh3–/–) exhibited significant decreases in colon length when 
compared with that in WT mice; repeated DSS-induced colon 
injury and healing is known to cause colon shortening. Surprising-
ly, there were no additional decreases in the colon length of Aag–/– 
Alkbh2–/– or Aag–/–Alkbh3–/– mice as compared with that of Aag–/– 
mice, suggesting an epistatic relationship between Aag and Alkbh2 
and between Aag and Alkbh3. In this experimental cohort, all of the 
mice developed colon tumors, and Aag–/– and Aag–/–Alkbh2–/– mice 
developed significantly more colon tumors than WT mice (Figure 
3C). The Aag–/–Alkbh3–/– mice also trended toward increased tumor 
multiplicity, but this did not quite reach statistical significance 
(P = 0.078). Again, these results suggest an epistatic relationship 
between Aag and the Alkbh genes, which will be considered further 
in the Discussion. Histopathological criteria indicate no signifi-
cant increases in disease severity for Aag–/–Alkbh2–/– mice compared 
with that for WT mice (Supplemental Figure 1B). However, we did 
observe a significant increase in the criteria of dysplasia and area 
affected for Aag–/–Alkbh3–/– mice compared with that for all other 
genotypes; interestingly, as mentioned above, this did not trans-
late into increased tumor formation in the Aag–/–Alkbh3–/– mice but 
does suggest that these mice may be prone to develop tumors 
that are broad based, with a higher grade of dysplasia.
Aag–/–Alkbh2–/–Alkbh3–/– triple-knockout mice exhibit extreme 
sensitivity to AOM/DSS treatment. Since the addition of an 
ALKBH2 or ALKBH3 deficiency had little effect in the Aag–/– 
mice, it was necessary to construct the triple mutant strain 
to further explore the interaction of AAG-initiated base exci-
sion repair and ALKBH-mediated direct reversal of DNA base 
damage in protecting against inflammation in the colon. We 
therefore tested the susceptibility of Aag–/–Alkbh2–/–Alkbh3–/– 
triple mutant mice to AOM/DSS treatment. To our surprise, 
all of the triple mutant mice (n = 29) became moribund 
between 2 and 3 days after the first 5-day DSS cycle (Figure 4A). 
Histopathological analysis revealed that Aag–/–Alkbh2–/–Alkbh3–/– 
mice exhibited massive intestinal injury, with a pathological diag-
nosis of severe acute necrotizing colitis. The lesions were observed 
predominantly in the transverse and distal colon, occasionally 
to a milder degree in the proximal colon, and never in the small 
intestine. The colonic lesions in the Aag–/–Alkbh2–/–Alkbh3–/– mice 
exhibited mucosal (surface and crypt epithelial) degeneration, 
necrosis with edema, and extensive areas of loss of tissue archi-
tecture and substantial neutrophil infiltration (Figure 4B). The 
corresponding WT and Aag–/– controls completed the 5 cycles of 
the AOM/DSS treatment regimen, and, accordingly, these mice 
exhibited colon hyperplasia, epithelial dysfunction, and increased 
inflammation in the distal colon (Figure 4B).
AOM, a SN1 colonotropic alkylating agent, and DSS, an intesti-
nal epithelial irritant, each induce colon-specific damage (43, 45). 
To determine which agent was responsible for the extreme sensi-
tivity observed in the Aag–/–Alkbh2–/–Alkbh3–/– triple mutant mice, 
we examined whole-body sensitivity to AOM in the Aag–/–Alkbh2–/– 
Alkbh3–/– mice by determining their approximate LD50. As illustrated 
in Table 1, Aag–/–Alkbh2–/–Alkbh3–/– mice did not exhibit increased 
whole-body sensitivity to AOM when compared with Aag–/– mice; 
Table 1
Approximate LD50 of alkylating agents for various  
mouse strains
 Approximate LD50
Mouse strain MMS AOM
WT 210 mg/kg 28 mg/kg
Aag–/– 210 mg/kg 18 mg/kg
Aag–/–Alkbh2–/–Alkbh3–/– 210 mg/kg 18 mg/kg
Figure 4
Aag–/–Alkbh2–/–Alkbh3–/– mice do not survive AOM/DSS treatment. 
(A) Kaplan-Meier survival curves illustrate complete lethality of 
Aag–/–Alkbh2–/–Alkbh3–/– mice following the first DSS cycle. (B) 
H&E-stained sections of colons harvested 2 days following DSS 
withdrawal (12 days after AOM dose) in Aag–/–Alkbh2–/–Alkbh3–/– 
mice and at the completion of the AOM/DSS treatment (100 days 
after AOM dose) in WT and Aag–/– mice. Consistent with the com-
pletion of the AOM/DSS treatment in the WT and Aag–/– cohorts, 
their colons exhibited regions of hyperplasia, inflammation, and 
minimal dysplasia. Scale bar: 100 μm. The asterisk indicates sub-
mucosal edema and associated scattered inflammatory cells; the 
arrow indicates epithelial erosion and necrosis.
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however, both Aag–/– and Aag–/–Alkbh2–/–Alkbh3–/– mice did appear 
to be slightly more sensitive to AOM when compared with WT 
mice. This slight increase in whole-body sensitivity to AOM cannot 
explain the surprising lethality of the Aag–/–Alkbh2–/–Alkbh3–/– mice 
during the AOM/DSS experiment, in which AOM was adminis-
tered at a dose lower than this LD50. We also examined whole-body 
sensitivity to the prototypical SN2 alkylating agent methylmethane 
sulfonate (MMS) and found that WT, Aag–/–, and Aag–/–Alkbh2–/–
Alkbh3–/– mice all displayed the same approximate LD50 (Table 1). 
Together, these data indicate that Aag–/–Alkbh2–/–Alkbh3–/– mice 
did not exhibit significantly increased susceptibility to SN1 or SN2 
alkylating agents, indicating that the extreme pathology observed 
Figure 5
DSS treatment is lethal to Aag–/–Alkbh2–/–Alkbh3–/– mice. (A) Kaplan-Meier survival curves of WT (n = 11), Aag–/– (n = 9), and Aag–/–Alkbh2–/–
Alkbh3–/– (n = 11) mice following 1 5-day cycle of DSS (2.5%). (B) Examples of colon pathology when the mice became moribund (2 days after 
DSS withdrawal, 7 days following start of DSS treatment) in Aag–/–Alkbh2–/–Alkbh3–/– mice. WT and Aag–/– mice are shown at completion of study 
(8 days after DSS withdrawal, 13 days after start of DSS treatment). (C and D) Levels of (C) εA base lesions and (D) 1,N2-εG base lesions are 
quantitated from colonic epithelium for WT, Aag–/–, and Aag–/–Alkbh2–/–Alkbh3–/– mice under untreated conditions (day 0), immediately following 
DSS (1.75%) withdrawal (day 5), and 4 days following DSS withdrawal (day 9). Statistical significance was determined by 2-way ANOVA with 
Bonferroni post test. Data are shown as the mean ± SD. (E) H&E-stained colon sections are shown from all mice 7 days following start of DSS 
treatment. (F) Histopathological scores of epithelial defects, mucosal degeneration, edema, inflammation, and hyperplasia are shown for WT 
(n = 10), Aag–/– (n = 10), and Aag–/–Alkbh2–/–Alkbh3–/– (n = 5) mice harvested 7 days following initiation of DSS (2.5%) treatment. Data represent 
mean ± SEM. (B and E) Asterisk indicate edema; arrows indicate epithelial ulceration. Scale bar: 100 μm.
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in the triple mutant mice following AOM/DSS treatment is not 
due to AOM sensitivity. We next explored whether Aag–/–Alkbh2–/– 
Alkbh3–/– mice are specifically sensitive to DSS-induced colitis.
AAG, ALKBH2, and ALKBH3 repair enzymes are essential to survive 
DSS-induced colitis. We challenged WT, Aag–/–, and Aag–/–Alkbh2–/–
Alkbh3–/– mice with a single 5-day cycle of DSS (2.5%) to determine 
whether DSS-induced disruption of the colonic mucosa on its own 
is sufficient to induce lethality in Aag–/–Alkbh2–/–Alkbh3–/– mice. 
Between 2 and 3 days following withdrawal of DSS, all the Aag–/– 
Alkbh2–/–Alkbh3–/– mice (n = 11) became moribund and required 
euthanasia, whereas the vast majority of WT and Aag–/– mice fully 
recovered from the DSS treatment but were euthanized at day 13 
for histological comparison with the Aag–/–Alkbh2–/–Alkbh3–/– mice 
(Figure 5A). As seen with AOM/DSS, the Aag–/–Alkbh2–/–Alkbh3–/– 
mice exposed to DSS alone exhibited severe intestinal (colonic) 
mucosal erosions/ulcerations, degeneration, necrosis, and edema. 
Since WT and Aag–/– mice survived 8 days after DSS withdrawal, 
their intestines, while exhibiting some regions of ulceration, also 
exhibited regions that had recovered from the intestinal injury, 
and these regions included regenerative crypts and intact mucosa; 
presumably, the regenerated colonic architecture was derived from 
surviving mesenchymal cells, stem cells, and any other cells that 
are required for such tissue repair (Figure 5B and ref. 46).
We next measured endogenous levels of εA (Figure 5C) and 
1,N2-εG base lesions (Figure 5D) in colonic epithelial cells of 
untreated and DSS-treated (1.75%) mice to determine whether the 
accumulation of unrepaired DNA base lesions may contribute to 
increased DSS toxicity in Aag–/–Alkbh2–/–Alkbh3–/– mice. Two-way 
ANOVA analysis illustrates that there was an accumulation of εA 
(P = 0.0012) and 1,N2-εG (P < 0.0001) DNA lesions in the genome 
of colonic epithelial cells following DSS treatment. At day 9 
(4 days after DSS withdrawal), Aag–/–Alkbh2–/–Alkbh3–/– mice exhib-
ited significantly increased levels of εA compared with those of 
WT mice (Figure 5C) and significantly increased levels of 1,N2-εG 
base lesions compared with those of both WT and Aag–/– mice 
(Figure 5D). This finding suggests that, like AAG, ALKBH2 and/
or ALKBH3 repairs 1,N2-εG base lesions; this substrate has not 
previously been illustrated for ALKBH2 or ALKBH3 (30, 47, 48). 
As these ε-base lesions can be transcription-blocking, replication-
blocking, mutagenic, and cytotoxic lesions, their accumulation 
likely explains, at least in part, the extreme DSS toxicity seen in 
the Aag–/–Alkbh2–/–Alkbh3–/– mice (49–51).
The reasons why Aag–/–Alkbh2–/–Alkbh3–/– mice do not survive 
DSS treatment may include the following: they develop more 
severe intestinal lesions than WT mice; they are unable to regener-
ate functional tissue after injury; or both. We evaluated the first 
possibility by examining the intestinal lesions in all genotypes 2 
days following DSS withdrawal, when the Aag–/–Alkbh2–/–Alkbh3–/– 
mice became moribund. Surprisingly, all genotypes exhibited 
equivalently severe intestinal lesions with extensive edema, epi-
thelial necrosis, and inflammation infiltrates (Figure 5E). Histo-
pathological analysis illustrated similar levels of epithelial defects, 
mucosal degeneration, and edema in all genotypes (Figure 5F). 
Interestingly, the Aag–/–Alkbh2–/–Alkbh3–/– colons actually exhibited 
decreased scores for inflammation when compared with those 
of WT colons (P < 0.05); thus, even in the face of an apparently 
less severe inflammatory response, the Aag–/–Alkbh2–/–Alkbh3–/– 
mice went on to a much worse phenotype (Figure 5F). The Aag–/– 
Alkbh2–/–Alkbh3–/– mice also displayed less severe hyperplasia than 
WT mice, perhaps indicating an inability to respond appropriately 
to mucosal degeneration and epithelial defects or perhaps because 
the inflammatory response is muted (Figure 5F). Full-body gross 
examination and detailed histopathological analysis of most 
organs was also performed on WT, Aag–/–, and Aag–/–Alkbh2–/– 
Alkbh3–/– mice in untreated conditions as well as 2 days following 
DSS (2.5%) withdrawal. There were no obvious phenotypic differ-
ences among any of the genotypes in untreated conditions, and 
no significant pathological differences were found in DSS-treated 
mice, with the sole exception of the severe lesions observed in the 
transverse to distal colon. As severe colitis can result in intestinal 
bleeding and eventually anemia, we performed a complete blood 
count to determine whether the increased lethality in DSS-treated 
Aag–/–Alkbh2–/–Alkbh3–/– mice could be attributed to an increased 
penetrance of anemia. However, all genotypes exhibited equiva-
lent hematocrit, hemoglobin, white blood cell counts, and red 
blood cell counts that were within normal limits, indicating that 
the DSS-treated mice did not differentially succumb to anemia 
(Supplemental Figure 2).
Figure 6
Aag–/–Alkbh2–/–Alkbh3–/– mice are capable of recovering from ceru-
lein treatment. (A) H&E-stained sections of pancreata are shown from 
untreated WT and Aag–/–Alkbh2–/–Alkbh3–/– mice as well as following 
cerulein treatment. Mice recovered for either 24 hours or 7 days follow-
ing the 6 hourly injections of cerulein (50 μg/kg). Scale bar: 100 μm. 
(B) Pathology scores of cerulein-treated WT and Aag–/–Alkbh2–/– 
Alkbh3–/– mice, showing the sum of the scores for edema, inflamma-
tion, and acinar cell degeneration. Individual data points represent 
total pathological scores of individual mice, and horizontal bars denote 
the mean score of mice.
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In summary, although all mice exhibited severe intestinal lesions 
2 days after DSS withdrawal, the WT and Aag–/– mice survived, 
exhibiting visible tissue repair of the intestinal epithelium 6 days 
after DSS withdrawal, whereas Aag–/–Alkbh2–/–Alkbh3–/– mice were 
totally unable to recover from the same initial lesions (Figure 5B). 
The histopathological analysis of the colon suggested that Aag–/–
Alkbh2–/–Alkbh3–/– mice are unable to mount an appropriate tissue 
repair response following the DSS-mediated epithelial damage, 
resulting in a total inability to withstand DSS-induced colitis.
AAG, ALKBH2, and ALKBH3 repair enzymes protect against some 
but not all inflammatory challenges. Having established that Aag–/–
Alkbh2–/–Alkbh3–/– DNA repair-deficient mice are unable to sur-
vive the induction of colonic inflammation by DSS, we set out to 
determine the generality of this dramatic phenotype. We chose 
2 different kinds of inflammatory challenge: one that, like DSS 
exposure, is stimulated by bacterial cell constituents and a second 
that is not stimulated by bacterial cell constituents. We thus chal-
lenged WT and Aag–/–Alkbh2–/–Alkbh3–/– mice with either LPS to 
induce bacterial endotoxemia or with the hormone mimetic ceru-
lein to induce acute inflammation in the pancreas (pancreatitis). 
LPS, derived from the outer membranes of gram-negative bacteria, 
induces systemic inflammation that is mediated through TLR sig-
naling (52–54), and cerulein induces pancreatitis that is mediated 
through cholecystokinin receptor signaling (55).
Twenty-four hours following cerulein treatment, all mice exhib-
ited evidence of pancreatic damage, with edema and acinar cell 
degeneration and/or necrosis; however, there was no difference 
in disease severity among the genotypes (Figure 6A), just as there 
was no difference in initial colonic damage for DSS-treated mice. 
To determine whether recovery from such cerulein-induced dam-
age is impaired in the Aag–/–Alkbh2–/–Alkbh3–/– mice, we examined 
recovery from this pancreatic challenge. Surprisingly, both WT 
and Aag–/–Alkbh2–/–Alkbh3–/– mice exhibited comparable recovery 
after the cerulein treatment, as indicated by pancreatic pathology 
7 days following the acute pancreatic challenge (Figure 6). Thus, 
the induction of and recovery from cerulein-induced inflammato-
ry injury was equivalent between WT and Aag–/–Alkbh2–/–Alkbh3–/– 
mice. The results upon exposing mice to bacterial endotoxemia 
induced by LPS were very different. WT mice survived all LPS 
doses up to 30 mg/kg and only required euthanasia following 
treatment with 30 mg/kg LPS (Table 2). In contrast, Aag–/–Alkbh2–/– 
Alkbh3–/– mice were much more sensitive than WT mice to LPS; 
100% of Aag–/–Alkbh2–/–Alkbh3–/– mice succumbed to treatment at 
doses of 15 mg/kg LPS and above, although all survived at 12.5 
mg/kg LPS (Table 2). Together these experiments illustrate that 
Aag–/–Alkbh2–/–Alkbh3–/– mice are more susceptible than WT mice 
to some, but not all, inflammatory challenges and further suggest 
that this sensitivity may be specific to TLR-mediated inflamma-
tion that is induced upon exposure to bacterial constituents.
Discussion
Inflammation and cancer were linked together as early as 1863 
when Virchow noted that cancers often occur at sites of chronic 
inflammation (2). Bouts of chronic inflammation can result in 
cycles of tissue damage, cellular proliferation, and eventually tis-
sue repair (56). Following tissue injury, inflammatory cells initiate 
a complex response of chemical signals to repair the damaged tis-
sue. However, activated inflammatory cells rapidly release RONS 
as a mechanism to prevent bacterial infections and as a result cause 
deleterious DNA damage. Inflammatory cells also release chemical 
mediators, such as cytokines and chemokines that can directly (or 
indirectly through the induction of NF-κB and STAT-3) promote 
the proliferation of surrounding tissues, invasion and metastasis 
of tumor cells, and generation of a proangiogenic microenviron-
ment (57, 58). This strong relationship linking inflammation and 
cancer has resulted in the inclusion of “an inflammatory environ-
ment” as an emerging hallmark in Hanahan and Weinberg’s hall-
marks of carcinogenesis (59).
Pattern recognition receptors (PRR) are important mediators of 
IBD, with evidence coming from both genetic association studies 
and animal models (60). The recognition of commensal bacteria by 
TLRs and the resulting MYD88-dependent signaling cascade are 
essential for regaining intestinal homeostasis following DSS treat-
ment (60–62). Further, NOD-like receptors, the inflammasome, 
and the downstream mediator IL-18 are also required for proper 
host responses to DSS treatment (63). Accordingly, numerous 
proteins in these pathways (notably MYD88, TLR2, TLR4, IL-1R, 
IL-18R, among others) are essential in preventing DSS-induced 
lethality; mice deficient in these proteins exhibit decreased survival 
and increased morbidity following DSS treatment (64–66). Since 
the majority of mouse models hitherto reported to display dra-
matically increased DSS sensitivity have defects in PRR signaling, 
it was surprising to find that Aag–/–Alkbh2–/–Alkbh3–/– mice exhibit 
DSS sensitivity comparable to that observed in Myd88–/– mice (65). 
In fact, 2 recent studies have demonstrated connections between 
DNA damage responses and pattern recognition receptors (PRR) 
responses mediated by MYD88. Salcedo et al. (67) reported that 
Myd88–/– colonic tissue shows altered regulation of numerous 
DNA-damage genes (i.e., Parp1, Msh2, Msh3, Atm, and Atr) follow-
ing AOM/DSS treatment, and Menendez et al. (68) reported that 
the human TLR gene family is integrated into the p53/DNA dam-
age response network. These observations, together with the data 
presented here, indicate an important role for DNA repair in regu-
lating intestinal homeostasis following DSS treatment.
IBD is a well-established example of chronic inflammation 
resulting in enhanced tumor risk, with patients with IBD exhib-
iting a 3- to 5-fold greater risk of cancer (3). Here, the episodic 
inflammation that occurs with repeated flare-ups in patients with 
IBD was simulated by the colonic irritant DSS in WT and numer-
ous DNA repair-deficient mice. We determine that deficiencies in 
the direct DNA repair proteins ALKBH2 and ALKBH3 resulted in 
greater susceptibility to inflammation-associated colon cancer. 
As we have shown previously, the absence of AAG activity also 
increases susceptibility in this carcinogenesis model, likely due 
to the wide variety of DNA lesions it repairs (10, 69–71). Exam-
Table 2
Sensitivity of WT and Aag–/–Alkbh2–/–Alkbh3–/– mice  
to LPS treatment
 Genotype
LPS (mg/kg) WT Aag–/–Alkbh2–/–Alkbh3–/–
12.5 0/3 0/3
15 0/4 5/5
20 0/3 3/3
30 3/3 2/2
The results are illustrated as the number of mice that succumb to LPS 
treatment with 7 days/the number of mice treated at each LPS dose.
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ining AOM/DSS-mediated tumorigenesis in numerous knock-
out mouse models allowed us to examine functional overlap 
and possible redundancy between AAG, ALKBH2, and ALKBH3 
in vivo. The increased tumor multiplicity observed in Aag–/– and 
Alkbh2–/– single-knockout mice illustrates the protective roles of 
these proteins in inflammation-associated carcinogenesis and sug-
gests that other repair proteins are unable to fully compensate in 
their absence. Additionally, we observed a synergistic increase in 
tumorigenesis in the Alkbh2–/–Alkbh3–/– mice, compared with that 
in Alkbh2–/– and Alkbh3–/– mice. Despite their overlap in DNA base 
substrates (Figure 1), AAG is unable to fully compensate in the 
absence of the 2 ALKBH proteins. We were surprised to find no 
additivity in tumorigenesis in the Aag–/–Alkbh2–/– or Aag–/–Alkbh3–/– 
mice compared with that in the relevant single mutants, indicating 
that AAG may be dominant to any additional phenotypic effect 
caused by absence of ALKBH2 or ALKBH3 and suggesting a pos-
sible epistatic relationship. Since AAG can bind to a number of 
ALKBH enzyme substrates, it is not hard to imagine that under 
certain circumstances AAG may facilitate ALKBH enzyme bind-
ing. Alternatively, it is possible that we failed to observe additivity 
in Aag–/–Alkbh2–/– or Aag–/–Alkbh3–/– mice because we reached an 
upper threshold in colon shortening and the number of tumors 
that develop following AOM/DSS treatment. This could prevent 
us from observing additional sensitivity/tumors in the Aag–/– 
Alkbh2–/– or Aag–/–Alkbh3–/– mice. Interestingly, Aag–/–, Aag–/– 
Alkbh2–/–, Aag–/–Alkbh3–/–, and Alkbh2–/–Alkbh3–/– mice all exhibited 
tumor multiplicity of approximately 20 tumors per mouse, which 
is similar to the maximum number of tumors typically reported 
for mice exhibiting increased susceptibility to AOM/DSS-induced 
carcinogenesis (43, 66, 72).
Our most surprising finding was that a single cycle of DSS-
induced colitis resulted in absolute lethality in Aag–/–Alkbh2–/–
Alkbh3–/– triple-knockout mice. This striking phenotype differs 
dramatically from the various double mutant combinations, 
which can survive up to 5 DSS cycles (during AOM/DSS treat-
ment). During the AOM/DSS treatment, all of the Aag–/–Alkbh2–/– 
Alkbh3–/– mice succumbed to severe necrotizing colitis follow-
ing the first DSS cycle, indicating that DNA repair mediated by 
AAG, ALKBH2, and ALKBH3 is absolutely essential for colon 
homeostasis, colon tissue repair, and whole-animal survival dur-
ing acute inflammatory conditions. It is important to note that 
following 1 cycle of 2.5% DSS, all genotypes, including WT, devel-
oped equivalently severe intestinal ulcerations, and the extent of 
epithelial defects was the same for all the genotypes. Interest-
ingly, the Aag–/–Alkbh2–/–Alkbh3–/– mice exhibited decreased his-
topathological scores for inflammation and hyperplasia com-
pared with those of WT mice, indicative of an impaired response 
in these animals. Thus, Aag–/–Alkbh2–/–Alkbh3–/– mice are sim-
ply unable to recover from the DSS-induced epithelial lesions. 
Importantly, Aag–/–Alkbh2–/–Alkbh3–/– mice exhibited increased 
sensitivity to LPS-mediated endotoxemia, although they were no 
more sensitive than WT mice to cerulein-induced pancreatitis. 
These differences perhaps reflect the fact that cerulein induces 
inflammation via cholecystokinin receptors, whereas DSS and 
LPS both induce inflammation via TLR-mediated signaling (54, 
55). We speculate that TLR-mediated signaling may involve the 
induction of Aag, Alkbh2, and Alkbh3 in cells that is crucial for 
colonic tissue repair and that in the absence of functional AAG, 
ALKBH2, and ALKBH3 repair enzymes, these cells simply do not 
survive exposure to RONS.
Remarkably, although the Aag–/–Alkbh2–/–Alkbh3–/– mice exhibited 
increased sensitivity to certain inflammatory challenges, a defi-
ciency in these 3 DNA repair proteins did not significantly affect 
their ability to survive exposure to 2 different genotoxic DNA 
methylating agents (AOM and MMS). This suggests that the DNA 
base lesions induced during an inflammatory response to DSS or 
LPS are different than those induced by AOM and MMS, presum-
ably reflect the generation of ε-base lesions but not methylated-
base lesions. Consistent with this, Aag–/–Alkbh2–/–Alkbh3–/– mice 
exhibited increased levels of toxic and mutagenic εA and 1,N2-εG 
in colonic epithelial cells following DSS treatment. The in vivo 
studies reported here suggest that there is substantial redundancy 
among the 3 repair proteins, AAG, ALKBH2, and ALKBH3, and 
that together they provide enough DNA repair to prevent the 
lethality induced by the inflammation associated with DSS or 
LPS exposure. Although substrate overlap among these proteins 
was previously reported (37, 69), we provide in vivo evidence that 
no other DNA repair activity is able to adequately compensate in 
the absence of AAG, ALKBH2, and ALKBH3 during TLR-mediated 
acute inflammatory stress. Further, the redundancy among these 
3 repair proteins underscores the importance of DNA repair for 
coping with inflammatory stresses that include both acute and 
chronic inflammation. We propose that AAG, ALKBH2, and 
ALKBH3 may be potential targets for genetic studies of IBD and 
human colorectal cancer. Indeed, AAG levels have already been 
shown to be elevated in inflamed regions, compared with those in 
uninflamed regions, of the colon in patients with UC (73). Similar 
monitoring of ALKBH2 and ALKBH3 levels in patients with IBD 
may also be warranted.
Methods
Animals. Aag–/–, Alkbh2–/–, and Alkbh3–/– mice were described previously 
(25, 74). The Alkbh2–/–Alkbh3–/– mice (on a mixed C57BL/6 129Sv/Ev back-
ground) were rederived upon arrival at Massachusetts Institute of Technol-
ogy. All mice used for experiments were on a mixed B6/129 background. 
Age-matched mice of both genders were 6–10 weeks old at the start of the 
treatment regimen.
Treatments. We used the combination of AOM and DSS to induce chronic 
colitis and colorectal cancer (10, 43). This treatment consists of a single 
dose of 12.5 mg/kg AOM (Midwest Research Institute, NCI Chemical 
Repository) injected i.p., followed by 5 cycles of DSS. One DSS cycle con-
sisted of 5 days of 2.5% DSS (MW 36,000–50,000, MP Biomedicals) in the 
drinking water, followed by 16 days of standard drinking water.
Whole-animal sensitivity to AOM and MMS (Sigma-Aldrich) was per-
formed as in Deichmann and LeBlanc (75). In brief, 5–6 animals were i.p. 
injected with a series of doses, each being 50% more than the previous 
dose. The lowest dose that induces signs of lethality within 30 days is 
the approximate LD50.
To induce acute pancreatitis, mice were i.p. injected hourly with ceru-
lein (Sigma-Aldrich) (50 μg/kg) for 6 injections. The mice were euthanized 
24 hours or 7 days following the first injection; the pancreata were har-
vested and fixed in formalin for histological analysis.
Sensitivity to LPS (from E. coli 026:B6, Sigma-Aldrich) was assessed by 
i.p. injecting a range of LPS doses (5 mg/kg to 30 mg/kg) and evaluating 
survival over a 7-day period.
Tissue collection. During the AOM/DSS experiment, mice were weighed 
and monitored regularly and euthanized if moribund or if they exhibited 
greater than 20% loss in body weight. Five days following the conclusion of 
the final DSS cycle, the cohorts were euthanized by CO2 asphyxiation. Sub-
sequently, each mouse was weighed, and the colon and spleen were carefully 
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dissected from each mouse. The colon (from cecum to anus) was removed 
from each mouse, washed with 1X PBS, and cut open lengthwise; the colon 
length was measured, and the number of polyps was counted. The spleen 
was weighed, and both the spleen and colon were fixed in 10% neutral buff-
ered formalin for 18 hours. Blood obtained from a cardiac puncture was 
collected in EDTA-containing blood collection tubes (Sardstedt) to perform 
a complete blood count (Hemavet 950FS, Drew Scientific Inc.).
Tissue processing and histopathology. Tissues were embedded in paraffin, 
sectioned at 5 μm, and stained with H&E at The David H. Koch Institute 
for Integrative Cancer Research at MIT Histology Core Facility. All H&E-
stained slides were then blindly scored by a board-certified veterinary 
pathologist (S. Muthupalani). AOM/DSS colons were scored as described 
previously (10). Colons from mice treated with a single DSS cycle were 
scored for the additional criteria of edema and mucosal necrosis/degen-
eration. Cerulein-treated pancreata samples were scored for the levels of 
inflammation, edema, and acinar cell degeneration/necrosis/loss on a 0–4 
scale; the sum of these criteria was the overall histopathological score.
Measurement of modified bases. Six- to eight-week-old male mice were admin-
istered 1.75% DSS for 5 days. To prolong survival, mice were supplement-
ed subcutaneously with 1 ml sterile 0.9% sodium chloride on day 8 and 9. 
Colons were harvested from untreated mice (day 0), immediately follow-
ing DSS treatment (day 5), and 4 days following DSS withdrawal (day 9). 
Colonic epithelial cells were harvested as previously described (10). εA and 
1,N2-εG lesions were quantified as described previously (10, 76, 77). Measure-
ments were carried out on DNA prepared from 3 or more animals per group, 
with the following exceptions: Aag–/– (untreated), Aag–/–Alkbh2–/–Alkbh3–/– 
(untreated), and Aag–/– (day 5), all of which were prepared from 2 animals.
Statistics. Statistical analyses were performed using GraphPad Prism 
software. Data are represented as mean ± SEM or mean ± SD, as indi-
cated in figure legends. Statistical significance was determined by per-
forming Mann-Whitney test or 2-way ANOVA with Bonferroni post-test 
analysis. Kaplan-Meier survival curves were generated, and difference in 
survival was determined using the log-rank test. A P value was consid-
ered significant if P < 0.05.
Study approval. Mice were housed in an Association of Assessment and 
Accreditation of Laboratory Animal Care–accredited facility. All proce-
dures were approved by the Massachusetts Institute of Technology Com-
mittee on Animal Care.
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